LEADER 01803nam  2200421   450 
001 9910583361803321
005 20230120002633.0
010   $a0-12-812440-7
010   $a0-12-812439-3
035   $a(CKB)3710000001442213
035   $a(MiAaPQ)EBC4901161
035   $a(EXLCZ)993710000001442213
100   $a20170727h20172017  uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aTreating life-threatening bleedings $edevelopment of recombinant coagulation factor VIIa /$fUlla Hedner
210  1$aLondon, England :$cAcademic Press,$d2017.
215   $a1 online resource (215 pages)
320   $aIncludes bibliographical references at the end of each chapters and index.
327   $aClassical bleeding disease -- My encounter with hemophilia -- The first years at novo nordisk -- The development of recombinant FVIIa -- The futher use and development of rFVIIa -- Legal issues regarding the use of rFVIIa in hemophilia patients with inhibitors -- Treatment with rFVIIa in Malmo? --Mechanism of action and dosage -- The continued development of rFVIIa during the 2000s -- Three different descriptions of how rFVIIa was developed -- Some final remarks.
606   $aBlood coagulation factors
606   $aBlood coagulation factor VIII
606   $aBlood coagulation disorders$xTreatment
615  0$aBlood coagulation factors.
615  0$aBlood coagulation factor VIII.
615  0$aBlood coagulation disorders$xTreatment.
676   $a612.115
700   $aHedner$b U$g(Ulla),$0855306
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910583361803321
996   $aTreating life-threatening bleedings$91909491
997   $aUNINA